You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

94 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Aug 2023
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Oct 2017
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Adjuvant, Curative
May 2019
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Curative
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
May 2019
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Jan 2018
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Curative
Sep 2019
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
May 2023
Regimen
Cancer Type:
Endocrine, 
Pancreatic Neuroendocrine, 
Genitourinary, 
Renal cell / Kidney
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    Belzutifan – For the treatment of adult patients with von Hippel-Lindau (vHL) disease, based on criteria
Apr 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Nov 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
May 2019

Pages